ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Longer Chemo Regimen Offers Better DFS For Premenopausal Breast Cancer

January 31, 2003

Interactive R01 Scores Vary widely, Result Of separate Review

June 11, 1993

NRC Undertake Diet, Nutrition And Cancer , Plans Meeting Nov. 6

September 26, 1980

Who Writes NCI’s bypass Budget anyway>? Editor’s name Revealed

May 14, 1993

This month’s 8-page Business & Regulatory Report included in this issue.

January 30, 2004

ACCC Preliminary Report on DRGs Finds Case Mix Can Alter Profit/ Loss Pictures

March 29, 1985